Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility
Authors' conclusion
ZA treatment as a component of clinical care was associated with significant declines in fracture rate in this cohort of children and young adults with skeletal fragility.
Study context
- Population
- Children and young adults aged 0 to 21 years treated with zoledronic acid (ZA) for skeletal fragility between 2010 and 2017 at an academic medical center; 65 male
- Participants
- 102 children
- Exposure
- Fracture rate before vs during ZA treatment
- Primary skeletal fragilityn = 39
- Secondary skeletal fragilityn = 63
- Outcome
- Change in annualized fracture rate
Methodological detailssingle academic medical center, before–after (pre- vs on-treatment), ZA prescribed at discretion of the treating clinician using a standardized protocol
- Single academic medical center
- Before–after (pre- vs on-treatment)
- ZA prescribed at discretion of the treating clinician using a standardized protocol
Main finding
As reported in the abstract
Annualized fracture rate, overall (fractures per year) · median treatment duration 1.8 (IQR 0.6-3.0) years
- Overall median fracture rate before ZA
- 0.6 (IQR 0.3-1.1) fractures per year
- Overall median fracture rate on ZA
- 0 (IQR 0-0.4) fractures per year
- Decrease in fracture rate
- P < .001
Observational data: associations, not effects.
Secondary outcomes
Annualized fracture rate by form of skeletal fragility
- Primary skeletal fragility: fracture rate before to on ZA
- 1.0 [IQR 0.6-1.5] to 0.3 [IQR 0-0.6]
- Secondary skeletal fragility: fracture rate before to on ZA
- 0.5 [IQR 0.1-0.8] to 0 [IQR 0-0.3]
- Significant reductions in both forms
- P < 0.001 for both
Long bone and long bone plus spine fracture rates
- Significant reductions in fracture rate persisted when limited to long bone or long bone plus spine fractures
Original publication
Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility. J Clin Endocrinol Metab. Published 26 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →